XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months EndedNine Months Ended
(in millions)2024202320242023
Equipment & Instruments$138 $148 $402 $480 
CAD/CAM131 128 367 370 
Connected Technology Solutions269 276 $769 $850 
Essential Dental Solutions369 347 $1,108 $1,110 
Orthodontics83 83 $276 $255 
Implants & Prosthetics158 169 512 526 
Orthodontic and Implant Solutions241 252 $788 $781 
Wellspect Healthcare72 72 $223 $212 
Total net sales$951 $947 $2,888 $2,953 

Net sales disaggregated by geographic region for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months EndedNine Months Ended
(in millions)2024202320242023
United States$374 $356 $1,089 $1,069 
Europe347 354 1,110 1,153 
Rest of World230 237 689 731 
Total net sales$951 $947 $2,888 $2,953 

Contract Assets and Liabilities

The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer orthodontic aligner treatments where the performance obligation has not yet been satisfied. The Company recorded deferred revenue of $123 million and $67 million in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at September 30, 2024. The Company recorded deferred revenue of $91 million and $57 million in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2023. During the three and nine months ended September 30, 2024, the Company recognized approximately $14 million and $77 million of net sales, respectively, which was previously deferred as of December 31, 2023. During the three and nine months ended September 30, 2023, the Company recognized approximately $12 million and $59 million, respectively, which was previously deferred as of December 31, 2022. The Company expects to recognize most of the remaining deferred revenue in net sales within the next twelve months.
Allowance for Doubtful Accounts

Accounts and notes receivable-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $15 million at September 30, 2024 and $17 million at December 31, 2023. For the three and nine months ended September 30, 2024 and 2023, changes to the provision for doubtful accounts, including write-offs of accounts receivable that were previously reserved, were not significant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.